ArticleDiabetes, obesity & metabolism2026
Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsTo evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. MATERIALS AND
methodsWe conducted a population-based cohort study using South Korean National Health Insurance Service claims data from 2010 to 2022. Adults aged 18 years or older with type 2 diabetes who initiated oral antiarrhythmic therapy (amiodarone or comparator agents) while on sulfonylurea treatment between 1 January 2011 and 31 December 2022, were included. The first dispensing date of an antiarrhythmic agent while on sulfonylureas was the index date. Patients with prior use of first-generation sulfonylureas, meglitinides, insulin, or antiarrhythmics, or those initiating multiple antiarrhythmic drugs on the index date were excluded. The primary outcome was severe hypoglycemia, defined as hospital admission or emergency department visits with a primary diagnosis of hypoglycemia. Propensity score overlap weighting and weighted Cox models were applied.
resultsAmong 12 730 eligible patients, 5325 (41.8%) initiated amiodarone and 7405 (58.2%) initiated comparator antiarrhythmics. Mean age was higher in the amiodarone group (69.2 vs. 67.6 years). After weighting, amiodarone initiation was associated with a higher risk of severe hypoglycemia compared with initiation of comparator antiarrhythmics (weighted HR 1.92; 95% CI, 1.12-3.30). The increased risk persisted across multiple sensitivity and subgroup analyses.
conclusionsInitiation of amiodarone in patients receiving sulfonylureas was associated with a higher risk of hypoglycemia compared with other antiarrhythmics. Given the continued use of sulfonylureas in diabetes care, this finding highlights the need for caution and close monitoring during their concomitant use with amiodarone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.